Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5529_Библиотеки_им_академика_М_И_Перельмана
.pdf
344 Bioinformatics of Autoimmune Diseases
approaches that can adapt to patient-specic molecular proles, a demand that increases both the
complexity and the cost of therapy development.
Durability and regulation of gene expression also present technical and clinical challenges.
While long-term expression of therapeutic genes is desirable in monogenic disorders, in autoimmunity, persistent overexpression of an immunomodulatory gene could disrupt immune
homeostasis and lead to unintended consequences. For example, excessive expression of IL-10
or FOXP3 could result in systemic immunosuppression or impair host defenses against infections and tumors. Conversely, transient expression may be insufcient to induce durable tolerance
or reverse established autoimmune pathology. Achieving the right balance requires nely tuned
expression systems, including inducible promoters or self-limiting RNA platforms, which are still
under development.
Finally, ethical and regulatory hurdles are substantial. Gene therapy involves manipulation of
the human genome, and while somatic editing is the standard in current trials, concerns about
unintended germline modication persist, especially with emerging in vivo editing technologies.
Regulatory agencies impose rigorous oversight on clinical trials involving gene therapy, requiring
extensive preclinical safety data and long-term patient follow-up. Moreover, the high cost of vector
manufacturing, GMP-grade cell processing, and individualized treatment design often translates
into limited accessibility and signicant nancial barriers. These challenges underscore the need
for continued innovation, policy reform, and equitable funding models to bring gene therapy for
autoimmunity from promise to practice.
10.5 SUMMARY
This chapter has explored the transformative potential of gene therapy as a novel and precise
approach to treating autoimmune diseases, which are marked by chronic immune system dysfunction and loss of tolerance to self-antigens. It began by establishing gene therapy’s core strategies
(gene augmentation, gene silencing, and gene editing) and their applications in correcting or modulating immune system defects at the molecular level. Gene augmentation focuses on introducing
functional genes to replace defective ones, while gene silencing aims to downregulate harmful gene
expression using RNA-based tools or CRISPRi. Gene editing, especially with CRISPR-Cas9, offers
the most precise approach by directly modifying disease-causing sequences in immune cells. Each
of these techniques brings unique advantages for restoring immune tolerance, controlling inammation, or suppressing autoreactive lymphocytes in a targeted and potentially long-lasting manner.
The chapter then examined the laboratory processes and delivery systems required for implementing these strategies, including the use of viral vectors, such as AAV and lentivirus, and emerging non-viral platforms like lipid nanoparticles. These methods enable both ex vivo and in vivo
applications depending on the disease context and therapeutic goal. Promising preclinical and
early-phase clinical trials were reviewed, such as IL-10 and IL-1Ra cytokine gene transfer in RA,
FOXP3 augmentation in regulatory T cells for T1D, and the use of MOG-specic CAR-Tregs in
MS. Further, CRISPR-based corrections of mutations in genes such as FOXP3 and DNASE1L3
were shown to hold signicant promise in reversing immune dysregulation. Antigen-specic tolerance through DNA and mRNA vaccines, and B-cell depletion through CD19 CAR-T cell therapies
in SLE, were also presented as emerging breakthroughs moving toward clinical translation.
In parallel with these scientic advancements, the chapter addressed key challenges that remain
in applying gene therapy to autoimmune diseases. These include the difculty of targeting specic
immune cells in a system-wide disease context, managing immune responses to viral vectors and
editing tools, and navigating the heterogeneity of autoimmune disorders which often involve complex, polygenic etiologies. Additionally, there is a critical need to optimize the durability of gene
expression and ensure tight regulatory control, especially for genes with potent immunomodulatory
effects. Ethical, regulatory, and nancial considerations were also discussed, highlighting the need
for responsible development, equitable access, and sustained innovation.
345 Gene Therapy and Autoimmune Diseases
In conclusion, gene therapy stands at the frontier of a new era in the treatment of autoimmune
diseases. While signicant scientic, technical, and ethical hurdles remain, ongoing research and
technological progress continue to push the boundaries of what is possible. The integration of
genome editing, cell engineering, and precision delivery offers the promise of not only symptom
management but also immune reprogramming and potential cure—transforming the landscape of
autoimmune therapeutics for future generations.
BIBLIOGRAPHY
Balasa, B., Boehm, B. O., Fortnagel, A., et al. (2001). Vaccination with glutamic acid decarboxylase plasmid
DNA protects mice from spontaneous autoimmune diabetes… Clinical Immunology, 99(2), 241–252.
https://doi.org/10.1006/clim.2001.5012
Brusko, T. M., Putnam, A. L., & Bluestone, J. A. (2008). Human regulatory T cells: Role in autoimmune
disease and therapeutic opportunities. Immunological Reviews, 223(1), 371–390. https://doi.org/
10.1111/j.1600-065X.2008.00637.x
Evans, C. H., Ghivizzani, S. C., & Robbins, P. D. (2018). Gene delivery to joints by intra-articular injection.
Human Gene Therapy, 29(1), 2–14. htt ps://doi.org/10.1089/hum.2017.181
Farh, K. K. H., et al. (2015). Genetic and epigenetic ne mapping of causal autoimmune disease variants.
Nature, 518(7539), 337–343.
Fransson, M., Piras, E., Burman, J., Nilsson, B., Essand, M., Lu, B., et al. (2012). CAR/ FoxP3-engineered T reg-
ulatory cells target the CNS and suppress EAE upon intranasal delivery. Journal of Neuroinammation,
9, 112. https://doi.org/10.1186/1742-2094-9-112
Gregersen, P. K., Lee, H. S., & Oksenberg, J. R. (2009). Genes and environment in the pathogenesis of multiple
sclerosis and other autoimmune diseases. Trends in Immunology, 30(12), 611–617.
Krienke, C., Kolb, L., Diken, E., et al. (2021). A noninammatory mRNA vaccine for treatment of experi-
mental autoimmune encephalomyelitis. Science, 371(6525), 145–153. https://doi.org/10.1126/science.
aay3638
Mackensen, A., et al. (2022). Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Nature Medicine, 28, 2124–2132. https://doi.org/10.1038/s41591-022-02017-5
Mease, P. J., Wei, N., Fudman, E. J., et al. (2010). Safety, tolerability, and clinical outcomes after intraarticular
injection of rAAV2-TNFR:Fc: Results of a phase 1/2 study. Journal of Rheumatology, 37(4), 692–703.
https://doi.org/10.3899/jrheum.090817
Raychaudhuri, S., Remmers, E. F., Lee, A. T., et al. (2008). Common variants at CD40 and other loci confer
risk of rheumatoid arthritis. Nature Genetics, 40(10), 1216–1223. https://doi.org/10.1038/ng.233
Sadelain, M., Rivière, I., & Riddell, S. R. (2017). Therapeutic T cell engineering. Nature, 545(7655), 423–431.
https://doi.org/10.1038/nature22395
Sisi ra k, V., et al. (2016). Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell,
166(1), 88–101. https://doi.org/10.1016/j.cell.2016.05.034
Index
16S rRNA, 37, 93, 287–88, 290, 295
1000 genomes project, 68, 111, 215, 222
A
ADEX, 99–101, 160, 162– 63
AIRE, 11, 47, 54, 61– 62
ALPS, 58, 61
A N NO VA R, 205, 209, 217–22, 339
A NO VA , 178, 180–87, 189, 198, 202
A SV, 288, 295–98, 300, 303
ATAC-Seq, 36, 254–77
B
B cell receptor, 9, 45
B cells, 4, 6–7, 9–11, 14 , 16, 19–20
BAM, 110, 175–76 , 178, 197
BED format, 109, 235, 2 41
Benjamini-Hochberg, 68, 91, 179–82
Biopython, 102, 106–7, 112 –13, 115 –16
BLAS T, 106, 14 4, 306, 322, 341
Bonferroni correction, 68
BWA , 71, 74, 95,
BWA -M E M, 209, 213, 234
205, 209
C
CAPS, 59, 63
CAS9, 37, 72, 333–37, 343–44
ChIP-Seq, 87, 89–91, 95–96
C li nVa r, 98, 101–2
Cohen’s d, 183 –85
Complement system, 3, 40, 51–52, 57–58,
204, 206
Concoct, 306, 321
Copy number variation, 45, 51, 65, 204
CPG, 55, 87, 284, 286
CPM, 80, 177, 18 5–86
CRISPR, 37, 72, 274 –75, 333–37
CRISPR-CAS9, 334–36, 343–44
Crohn, 28–30, 40 –45
Cytokines, 1–4, 7–14, 16, 18 –20
D
DADA 2, 288–89, 295, 297–98, 305, 330
DA M P, 3–4, 13, 45
Deblur, 288, 295
Deletion, 49, 51–54
Dendritic cells, 1, 13, 31
DESeq2, 65, 75, 79–80, 90–91
DIAMOND, 306, 322–24, 326–27, 329
Differential expression, 36, 75, 78–80, 85
Disgenet, 65, 72, 100, 161– 62
DNA methylation, 55–56
, 95, 121, 165
DNA-protein interaction, 223, 225, 227, 229,
231–33
Downregulate, 60, 344
Drosha, 196
E
E-utilities, 102, 11 2–13 , 124, 162, 264
E-Utils, 102, 123
EDirect, 113
ENCODE, 68, 75, 95
Enhancer, 45, 53, 74, 87, 90, 95
Ensembl, 65, 97–98, 10 0, 109, 122, 129, 136
Ensembl API, 129
285–86, 329
Epigenetic regulation, 226, 254, 256, 258–59,
283, 286
Epigenomics, 36, 38, 56, 86, 230,
Epistatic interaction, 46
Exon, 6, 52–54, 61
Exon skipping, 53–54, 61
239, 273–75
F
F-test, 186
FASTA format, 106, 112 , 116–17, 144 , 147, 211, 271
fastp, 174, 197, 203
FASTQ, 108–9
FastQC, 71, 78, 85, 93
FDR, 228, 233, 235–38
Featurecounts, 78, 165, 176 , 197, 203
FOXP3, 7–8, 25–29, 34, 36–37
Frameshift, 43, 49–50, 53, 59, 61, 65, 71, 74
Freebayes, 71, 205, 209, 339
G
GATK, 71, 74, 94–95, 111
GenBank, 98, 100–102, 10 4, 106–7
GenBank format, 107, 162
Gene expression, 36, 38, 40 –41, 45–47, 50–52
Gene Expression Omnibus, 98, 163
Gene Ontology, 80,
Gene therapy, 37, 331–39, 341– 45
GeneCards, 65
Genetic variant, 204, 206–8, 211, 214 –15, 217–18
Genotypes and phenotypes, 99, 163
GEO, 98, 100 –101, 104, 10 9
Gliadin, 23
Gluten, 23–25
GO, 23, 80–81, 85, 91
GRCh38, 71, 74, 85, 89, 123
Greengenes, 93, 288, 330
GTEx, 68, 75, 95, 340
G WAS , 65–70, 72, 86, 94–96
194–95, 230, 342
347
348 Index
H
Hashimoto’s thyroiditis, 25–26
HISAT2, 65, 85, 165
HOMER, 239– 43, 245–52, 254, 262
Hydrogen bond, 223
I
I GV, 109, 263, 268, 272
Illumina, 69–71
Immune tolerance, 1, 7–8, 11, 17–18, 20 –21
Immunoglobulin, 9 –10, 26, 35, 172 , 206,
230, 282
Indel, 49–52, 57, 61– 62
Insertion, 49–50, 52–53
Integrative genomics viewer, 222, 263
Intron, 52–54, 61, 65
Intron retention, 53, 61
IPEX, 47, 54, 60–62, 225, 243, 337
K
Kaiju, 307–9, 311– 12, 320, 329
KEGG, 147– 56
KEGG pathway, 91, 147–52, 156, 158–59, 194
M
MA plot, 190–91, 200–201, 252
MAC, 3
MACS3, 232–42, 244–47, 252, 254
MA F, 67, 122–23
MAFFT, 295, 301–2
MaxBin, 306, 321
Metagenomics, 287, 289–90, 294, 305 –10
me ta SPAde s, 306, 321
Methylation, 38, 46, 55–56
MHC, 1, 3, 5–9, 11, 14–15, 20, 23, 26
Microbiome, 1, 18, 26, 28, 30, 33, 37–38
MicroRNA, 64–65, 76–77, 125, 127, 196, 286
Missense mutation, 48, 60, 96, 121, 220
Molecular mimicry, 16, 33, 40, 43, 92, 278–80, 329
Motif analysis, 244–45
Multiple sclerosis, 22–23
Myasthenia gravis, 33–34
, 225
N
NCBI, 49, 51, 65, 98–102
NCBI SRA, 125–28, 166–67
Neutrophils, 1–2, 8–9, 12, 16, 52, 171
NGS, 67, 70, 72–73, 75
Nonsense mutation,
Normalization, 79, 177
Nucleosome, 87, 223–25, 254, 256, 259–63
Nucleosome positioning, 223, 259– 61, 263,
269–70, 275
59
O
OMIM, 65, 99–101, 114, 124–25, 162–63
OTU, 288, 295–96
Oxford Nanopore, 74, 93, 206, 306, 343
P
PacBio, 73–74, 93, 306, 343
PA M P, 3–4, 13, 281–82, 284
PCA, 66–67
PCA plot, 187–88, 198–99, 202, 315 –16, 329
Peak, 227–30, 232–49, 252–55
Peak calling, 90, 110, 228, 230, 232–34
Peak enrichment, 89, 91, 96
Peptidoglycan, 28, 30, 50, 278, 282,
284, 286
Phagocytosis, 2–3, 9, 14, 57
Phosphorylation, 15, 56, 133, 146 ,
163,
225
Poisson distribution, 89, 237
Poly(A), 76–77, 165
Poly(dT ), 83
PPI, 156–58
Promoter, 40, 45, 50, 55–56
Protein-protein interaction, 39, 156–57
PTPN22, 18 , 20–21, 25–28, 33–34
PWM, 249–50
Q
QIIME2, 37, 65, 93, 96, 293–94, 296,
298, 304
R
RESTful, 102, 112 –13, 129, 134 –38,
141– 42
RESTful API, 102, 112 –13, 134–38,
141– 42
Rheumatoid arthritis, 12, 15–18, 41– 47
RNA polymerase, 223, 269
RNA-Seq, 65 –168, 173 –74, 176 –78 , 180
RNA sequencing, 164–65, 167, 169
RPKM, 79, 95
S
S ILVA , 93, 288–89, 293, 300, 330
SN P, 20–21, 36
SNPEff, 71, 74, 205, 209, 221, 339
Somatic gene rearrangement, 4
Somatic recombination, 5–6
Splicing, 6, 36
Splicing mutations, 52–55, 61– 62, 65
STAR, 121, 16 5, 174–76
Stop codon, 49–50, 54, 59, 61, 72
Structural variation, 57, 65, 99, 110–11
Sumoylation, 225
Systemic lupus erythematosus, 18 –19, 44,
46–47
, 45, 50, 52–55, 61– 63
T
T cells, 2, 4–9, 11–14
T-test, 178 –80, 189–90
TCR, 5–8, 11, 18, 20, 26, 40, 280, 282
TF footprinting, 263, 269–70
Thyroglobulin, 25–26, 28
Tn5 transposase, 88, 259–60
Index 349
TOBIAS, 36, 260, 263, 269–72, 275
TPM, 79, 95, 165, 236, 238
Transcript, 6, 45, 53–54
Transcription factor, 3, 8, 13, 23,
26, 158
Transcriptome, 38, 75–78, 84, 95
Translocation, 57, 61, 92, 279,
284–85, 330
Trimmomatic, 71, 121
Tu key, 183–85, 202
Type 1 diabetes mellitus, 20–21
U
UTR, 51, 70, 206, 217, 244
V
VCF, 111, 205, 207, 209, 214–21
V EP, 36, 65, 69, 71, 74, 95, 209, 339
Volcano plot, 189 –90, 199–200
W
Welch’s t-test, 179, 317, 328
WES, 69–72
WGS, 65, 67, 69, 72–74
Z
Zinc nger, 223–24
Соседние файлы в папке Библиотека им академика М.И. Перельмана